Niacin in cardiovascular prevention: mechanisms, efficacy, and safety
- 1 August 2007
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Lipidology
- Vol. 18 (4), 415-420
- https://doi.org/10.1097/mol.0b013e3282364add
Abstract
This review describes niacin's mechanism of action, efficacy in cardiovascular prevention, and safety. A G-protein-coupled receptor [GPR109A/HM74A, mouse PUMA-G (protein upregulated in macrophages by interferon-gamma)] was found to mediate the antilipolytic effect of niacin via inhibition of adenylyl cyclase in adipocytes. The same receptor in skin Langerhans cells mediates the common flushing side effect. The endogenous ligand for the receptor may be beta-hydroxybutyrate. Among nine controlled clinical trials using niacin, mostly combined with other drugs, statistically significant positive impact on clinical or anatomic cardiovascular end-points was found in seven, which represents a remarkably consistent record of benefit. Although niacin induces insulin resistance, deterioration of glycemic control in diabetes is usually minor, and there is no evidence of increased incidence of new onset diabetes. Hepatic toxicity is common with higher doses of sustained-release niacin but rare with immediate-release and extended-release niacin at doses up to 2000 mg/day. Extended-release and immediate-release niacin do not substantially potentiate myopathic effects when given in combination with statins. Recently developed understanding of the mechanisms, efficacy, and safety of niacin, along with progress in reducing the chief side effect of flushing, should enhance the use of this valuable agent for cardiovascular prevention.Keywords
This publication has 58 references indexed in Scilit:
- Antagonism of the prostaglandin D 2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humansProceedings of the National Academy of Sciences of the United States of America, 2006
- Influence of Extended-Release Nicotinic Acid on Nonesterified Fatty Acid Flux in the Metabolic Syndrome With Atherogenic DyslipidemiaThe American Journal of Cardiology, 2005
- Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)The American Journal of Cardiology, 2005
- Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) studyThe American Journal of Cardiology, 2004
- Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemiaThe American Journal of Cardiology, 1998
- Niacin Decreases Removal of High-Density Lipoprotein Apolipoprotein A-I But Not Cholesterol Ester by Hep G2 CellsArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Niacin-induced myopathyThe American Journal of Cardiology, 1994
- Efficacy and long-term adverse effect pattern of lovastatinThe American Journal of Cardiology, 1988
- Myolysis and Acute Renal Failure in a Heart-Transplant Recipient Receiving LovastatinThe New England Journal of Medicine, 1988
- Islet‐activating protein prevents nicotinic acid‐induced GTPase stimulation and GTP but not GTPγS‐induced adenylate cyclase inhibition in rat adipocytesFEBS Letters, 1983